Novel vaccine against Venezuelan equine encephalitis combines advantages of DNA immunization and a live attenuated vaccine

Irina Tretyakova, Igor S. Lukashevich, Pamela Glass, Eryu Wang, Scott Weaver, Peter Pushko

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

DNA vaccines combine remarkable genetic and chemical stability with proven safety and efficacy in animal models, while remaining less immunogenic in humans. In contrast, live-attenuated vaccines have the advantage of inducing rapid, robust, long-term immunity after a single-dose vaccination. Here we describe novel iDNA vaccine technology that is based on an infectious DNA platform and combines advantages of DNA and live attenuated vaccines. We applied this technology for vaccination against infection with Venezuelan equine encephalitis virus (VEEV), an alphavirus from the Togaviridae family. The iDNA vaccine is based on transcription of the full-length genomic RNA of the TC-83 live-attenuated virus from plasmid DNA in vivo. The in vivo-generated viral RNA initiates limited replication of the vaccine virus, which in turn leads to efficient immunization. This technology allows the plasmid DNA to launch a live-attenuated vaccine in vitro or in vivo. Less than 10. ng of pTC83 iDNA encoding the full-length genomic RNA of the TC-83 vaccine strain initiated replication of the vaccine virus in vitro. In order to evaluate this approach in vivo, BALB/c mice were vaccinated with a single dose of pTC83 iDNA. After vaccination, all mice seroconverted with no adverse reactions. Four weeks after immunization, animals were challenged with the lethal epidemic strain of VEEV. All iDNA-vaccinated mice were protected from fatal disease, while all unvaccinated controls succumbed to infection and died. To our knowledge, this is the first example of launching a clinical live-attenuated vaccine from recombinant plasmid DNA in vivo.

Original languageEnglish (US)
Pages (from-to)1019-1025
Number of pages7
JournalVaccine
Volume31
Issue number7
DOIs
StatePublished - Feb 4 2013

Fingerprint

Venezuelan Equine Encephalomyelitides
Attenuated Vaccines
live vaccines
encephalitis
Immunization
immunization
Vaccines
vaccines
horses
Venezuelan Equine Encephalitis Viruses
DNA
Vaccination
DNA Vaccines
Plasmids
Virus Replication
Technology
Venezuelan equine encephalitis virus
Togaviridae
plasmids
RNA

Keywords

  • DNA vaccine
  • Infectious DNA
  • Live attenuated virus
  • TC-83
  • VEE
  • Venezuelan equine encephalitis

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Novel vaccine against Venezuelan equine encephalitis combines advantages of DNA immunization and a live attenuated vaccine. / Tretyakova, Irina; Lukashevich, Igor S.; Glass, Pamela; Wang, Eryu; Weaver, Scott; Pushko, Peter.

In: Vaccine, Vol. 31, No. 7, 04.02.2013, p. 1019-1025.

Research output: Contribution to journalArticle

Tretyakova, Irina ; Lukashevich, Igor S. ; Glass, Pamela ; Wang, Eryu ; Weaver, Scott ; Pushko, Peter. / Novel vaccine against Venezuelan equine encephalitis combines advantages of DNA immunization and a live attenuated vaccine. In: Vaccine. 2013 ; Vol. 31, No. 7. pp. 1019-1025.
@article{cd1590a6809440b092283e4b79f20bd1,
title = "Novel vaccine against Venezuelan equine encephalitis combines advantages of DNA immunization and a live attenuated vaccine",
abstract = "DNA vaccines combine remarkable genetic and chemical stability with proven safety and efficacy in animal models, while remaining less immunogenic in humans. In contrast, live-attenuated vaccines have the advantage of inducing rapid, robust, long-term immunity after a single-dose vaccination. Here we describe novel iDNA vaccine technology that is based on an infectious DNA platform and combines advantages of DNA and live attenuated vaccines. We applied this technology for vaccination against infection with Venezuelan equine encephalitis virus (VEEV), an alphavirus from the Togaviridae family. The iDNA vaccine is based on transcription of the full-length genomic RNA of the TC-83 live-attenuated virus from plasmid DNA in vivo. The in vivo-generated viral RNA initiates limited replication of the vaccine virus, which in turn leads to efficient immunization. This technology allows the plasmid DNA to launch a live-attenuated vaccine in vitro or in vivo. Less than 10. ng of pTC83 iDNA encoding the full-length genomic RNA of the TC-83 vaccine strain initiated replication of the vaccine virus in vitro. In order to evaluate this approach in vivo, BALB/c mice were vaccinated with a single dose of pTC83 iDNA. After vaccination, all mice seroconverted with no adverse reactions. Four weeks after immunization, animals were challenged with the lethal epidemic strain of VEEV. All iDNA-vaccinated mice were protected from fatal disease, while all unvaccinated controls succumbed to infection and died. To our knowledge, this is the first example of launching a clinical live-attenuated vaccine from recombinant plasmid DNA in vivo.",
keywords = "DNA vaccine, Infectious DNA, Live attenuated virus, TC-83, VEE, Venezuelan equine encephalitis",
author = "Irina Tretyakova and Lukashevich, {Igor S.} and Pamela Glass and Eryu Wang and Scott Weaver and Peter Pushko",
year = "2013",
month = "2",
day = "4",
doi = "10.1016/j.vaccine.2012.12.050",
language = "English (US)",
volume = "31",
pages = "1019--1025",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "7",

}

TY - JOUR

T1 - Novel vaccine against Venezuelan equine encephalitis combines advantages of DNA immunization and a live attenuated vaccine

AU - Tretyakova, Irina

AU - Lukashevich, Igor S.

AU - Glass, Pamela

AU - Wang, Eryu

AU - Weaver, Scott

AU - Pushko, Peter

PY - 2013/2/4

Y1 - 2013/2/4

N2 - DNA vaccines combine remarkable genetic and chemical stability with proven safety and efficacy in animal models, while remaining less immunogenic in humans. In contrast, live-attenuated vaccines have the advantage of inducing rapid, robust, long-term immunity after a single-dose vaccination. Here we describe novel iDNA vaccine technology that is based on an infectious DNA platform and combines advantages of DNA and live attenuated vaccines. We applied this technology for vaccination against infection with Venezuelan equine encephalitis virus (VEEV), an alphavirus from the Togaviridae family. The iDNA vaccine is based on transcription of the full-length genomic RNA of the TC-83 live-attenuated virus from plasmid DNA in vivo. The in vivo-generated viral RNA initiates limited replication of the vaccine virus, which in turn leads to efficient immunization. This technology allows the plasmid DNA to launch a live-attenuated vaccine in vitro or in vivo. Less than 10. ng of pTC83 iDNA encoding the full-length genomic RNA of the TC-83 vaccine strain initiated replication of the vaccine virus in vitro. In order to evaluate this approach in vivo, BALB/c mice were vaccinated with a single dose of pTC83 iDNA. After vaccination, all mice seroconverted with no adverse reactions. Four weeks after immunization, animals were challenged with the lethal epidemic strain of VEEV. All iDNA-vaccinated mice were protected from fatal disease, while all unvaccinated controls succumbed to infection and died. To our knowledge, this is the first example of launching a clinical live-attenuated vaccine from recombinant plasmid DNA in vivo.

AB - DNA vaccines combine remarkable genetic and chemical stability with proven safety and efficacy in animal models, while remaining less immunogenic in humans. In contrast, live-attenuated vaccines have the advantage of inducing rapid, robust, long-term immunity after a single-dose vaccination. Here we describe novel iDNA vaccine technology that is based on an infectious DNA platform and combines advantages of DNA and live attenuated vaccines. We applied this technology for vaccination against infection with Venezuelan equine encephalitis virus (VEEV), an alphavirus from the Togaviridae family. The iDNA vaccine is based on transcription of the full-length genomic RNA of the TC-83 live-attenuated virus from plasmid DNA in vivo. The in vivo-generated viral RNA initiates limited replication of the vaccine virus, which in turn leads to efficient immunization. This technology allows the plasmid DNA to launch a live-attenuated vaccine in vitro or in vivo. Less than 10. ng of pTC83 iDNA encoding the full-length genomic RNA of the TC-83 vaccine strain initiated replication of the vaccine virus in vitro. In order to evaluate this approach in vivo, BALB/c mice were vaccinated with a single dose of pTC83 iDNA. After vaccination, all mice seroconverted with no adverse reactions. Four weeks after immunization, animals were challenged with the lethal epidemic strain of VEEV. All iDNA-vaccinated mice were protected from fatal disease, while all unvaccinated controls succumbed to infection and died. To our knowledge, this is the first example of launching a clinical live-attenuated vaccine from recombinant plasmid DNA in vivo.

KW - DNA vaccine

KW - Infectious DNA

KW - Live attenuated virus

KW - TC-83

KW - VEE

KW - Venezuelan equine encephalitis

UR - http://www.scopus.com/inward/record.url?scp=84872619099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872619099&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2012.12.050

DO - 10.1016/j.vaccine.2012.12.050

M3 - Article

C2 - 23287629

AN - SCOPUS:84872619099

VL - 31

SP - 1019

EP - 1025

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 7

ER -